Short term funding extension

Full Title:
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026

Summary#

This law is a large, multi-part appropriations and extension act. It (1) continues government funding at most 2025 levels for many agencies through January 30, 2026, and (2) contains full-year appropriations and program changes for Agriculture, the Legislative Branch, Military Construction and Veterans Affairs, FDA, and other items for fiscal 2026. It also extends many program authorities and short-term funding for health, Medicaid/Medicare rules, and certain veterans and agriculture programs.

Key changes:

  • Short-term continuing resolution: Agencies covered get funding at prior-year rates and authorities to operate until January 30, 2026, unless full-year appropriations are enacted sooner. The CR includes limits on starting new Defense projects and on using funds for new production not funded in 2025.
  • Agriculture funding and programs (Division B): Detailed FY2026 appropriations for USDA programs (research, SNAP/WIC/child nutrition, crop insurance, rural development, farm loan programs, Forest Service, FDA-related food programs). Many specific dollar amounts and program directions are in the bill.
  • Legislative Branch funding (Division C): FY2026 budgets for Senate, House, Capitol Police, Architect of the Capitol, Library of Congress, Government Publishing Office, and related accounts.
  • Military Construction and Veterans Affairs (Division D): Large FY2026 appropriations for military construction, family housing, and VA (medical services, medical facilities, benefits). The VA receives major sums for medical care, construction, and a new Cost of War Toxic Exposures Fund.
  • Extensions and program tweaks (Divisions E–G): One-year extensions of many agriculture authorities, public health programs, Medicare/Telehealth flexibilities, certain Medicaid DSH rules, and numerous temporary veterans authorities. The bill also creates or authorizes FDA over‑the‑counter (OTC) monograph user fees and sets rules for those fees.
  • Miscellaneous and policy riders (Division H): Many targeted directives, restrictions, notification requirements, and reporting rules for agencies; some funds are rescinded or repurposed.

What it means for you#

  • Federal employees / public servants

    • Funding continuity for many federal pay and operations through Jan 30, 2026. The bill bars federal agencies from initiating reductions in force during the CR period and allows funds to be apportioned to avoid furloughs.
    • Agencies must notify appropriations committees before major reorganizations, transfers, or IT changes.

  • Veterans and VA patients

    • VA gets large appropriations for medical services, community care, medical facilities, prosthetics, and benefits. Programs for toxic exposures, caregiver support, suicide prevention, telehealth, and women’s health all receive directed funding.
    • Several temporary authorities and programs for veterans (housing, homeless veterans grants, certain hearings or reporting deadlines) are extended for up to a year.

  • Farmers, ranchers, and rural communities

    • USDA programs (crop insurance, farm loans, conservation programs, rural water, broadband, distance learning, rural housing) receive funding and specific program direction. Some agriculture authorities are extended through 2026.
    • There are new or increased line items for research, extension, and community project funding.

  • SNAP/WIC/School nutrition recipients

    • Child nutrition and WIC programs receive multi‑billion dollar appropriations and specific funding for school breakfast/school lunch and related grants and equipment.

  • Health care providers and hospitals

    • Medicare extensions and temporary rules are continued or adjusted: telehealth flexibilities, low‑volume hospital payment rules, ambulance add‑ons, and hospice/quality measurement funding are extended or modified for short periods.
    • An FDA OTC monograph user‑fee system is authorized; FDA will assess fees on OTC facilities and use those fees for monograph rulemaking and other OTC activities.

  • Businesses regulated by FDA (OTC drugs)

    • A new user fee program for OTC monograph drugs starts in FY2026. Annual fees, fee-setting rules, and reporting requirements are in the bill; FDA must publish fee levels and reports.

  • Military construction contractors and local communities

    • New and continued military construction and family housing appropriations; some funds are subject to project-specific notifications and timing requirements.

  • Legislative branch and Capitol operations

    • Funding for Congress, Capitol Police, Architect of the Capitol, and related activities, including specified security and Member protection funds.

Expenses#

Estimated public cost: The Act both continues short-term funding for many programs and provides specific FY2026 appropriations in the bill. It authorizes many billions of dollars across agencies; the bill text lists many amounts (selected examples below).

Selected appropriations and funds in the law (not exhaustive):

  • Continuing funding through Jan 30, 2026 for many agencies at FY2025 rates (Division A).
  • Child Nutrition (USDA): $37,841,674,000 (available through Sept 30, 2027).
  • SNAP: $107,481,218,000 (includes reserves).
  • WIC: $8,200,000,000 (through Sept 30, 2027).
  • FDA (Salaries & Expenses): $6,957,972,000 (includes multiple user‑fee credits).
  • VA medical and related: large amounts (examples include $59,858,000,000 for VA Medical Services becoming available Oct 1, 2026; Cost of War Toxic Exposures Fund $52,676,000,000; full VA benefits and compensation lines are set across fiscal years).
  • Military Construction totals: multiple billions (e.g., Army, Navy, Air Force construction accounts listed with multi‑billion totals).
  • USDA research, rural development, conservation, and loan program totals are detailed in Division B (many line items).

Costs/trade-offs noted in the text:

  • The Act includes rescissions of unobligated balances in several accounts and directs transfers among some accounts (e.g., transfers for E‑7 Wedgetail program, transfers into Defense and HUD accounts). It also designates some amounts as emergency or disaster relief as noted.
  • The CR structure limits new starts and some procurement increases for the Department of Defense until full-year appropriations are enacted.
  • Many program extensions are short-term (generally to Jan 30, 2026), so long-term funding decisions remain to be made.

Proponents' View#

  • The bill appears intended to prevent a government funding lapse and to keep essential programs running while Congress completes full appropriations.
  • This could be seen as providing predictable short-term funding to hospitals, veterans, nutrition programs (SNAP/WIC/school meals), rural development, and national security programs.
  • Supporters may argue the bill funds specific priorities (VA health care and toxic‑exposure research, USDA commodity and rural programs, FDA resources for OTC drug rulemaking, and military construction) and includes oversight and notification rules to limit undesired changes during the continuing resolution.
  • The OTC monograph user‑fee program is presented as a way for FDA to have dedicated funds to modernize and finalize over‑the‑counter rules.

Opponents' View#

  • One concern is the high near‑term spending and many temporary extensions without longer‑term budget clarity; critics could say it delays tough appropriations choices.
  • The continuing resolution limits (for example on new DoD production starts and procurement increases) could delay program starts or complicate planning for agencies and contractors.
  • The bill contains many policy riders, reporting and notification requirements, and restrictions on agency actions (office closures, reassignments, regulations) that may be seen as micromanaging agencies or slowing necessary reforms.
  • Some program details remain dependent on future rulemaking or fee-setting (for example, OTC monograph fee levels and implementation), so predictability for industry and providers is limited until FDA issues implementing guidance and fee notices.

What is unclear

  • The bill sets many specific dollar amounts but leaves annual implementation details (for example, precise user‑fee schedules, exact timing for some transfers, and how some new funds will be allocated) to agencies or future notices. Where effects depend on later agency actions, the bill does not fully specify those details.